SynthesisFrontiers in endocrinology2024
Risk factors for erectile dysfunction in diabetes mellitus: a systematic review and meta-analysis.
Synthesis in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Metabolic syndrome and bladder cancer risk: a comprehensive evidence synthesis combining bibliometric and meta-analysis approaches.BMC urology · 2025Pooled it
- Impact of gestational diabetes mellitus on women's sexual function: a systematic review and meta-analysis.BMC endocrine disorders · 2024Pooled it
- Silence, stigma, and sexual health: experiences of sexual dysfunction among men living with diabetes in Ghana.BMC health services research · 2026Article
- Erectile dysfunction and sexual health counselling after myocardial infarction treated with percutaneous coronary intervention.Postepy w kardiologii interwencyjnej = Advances in interventional cardiology · 2026Article
- ICNPReports (MDPI) · 2026Article
- Analysis of patients with erectile dysfunction undergoing coronary angiography in Austria-a cross-sectional study.Wiener medizinische Wochenschrift (1946) · 2026Article
- Periodontitis as a potential amplifier of diabetes-related genitourinary complications: evidence gradients and mechanistic insights into the inflammation-microvascular injury axis.Frontiers in cellular and infection microbiology · 2026Review
- Guipi Decoction Attenuates Fibrosis and Oxidative Stress to Ameliorate Diabetic Erectile Dysfunction in Rats via the RhoA/ROCK Signaling PathwayEndocrine, metabolic & immune disorders drug targets · 2026Article
- Clinical characteristics of type 2 diabetes mellitus patients with erectile dysfunction.Frontiers in endocrinology · 2026Article
- Erectile dysfunction, type 2 diabetes, and cardiovascular disease: a narrative review and insights from a global real-world cohort analysis.Frontiers in clinical diabetes and healthcare · 2026Review
- Genetic biomarkers associated with risk and therapeutic response in erectile dysfunction: a systematic review.Frontiers in pharmacology · 2026Review
- From arthritis to erectile dysfunction: potential pathophysiological mechanisms and multidisciplinary integrated management.Frontiers in cell and developmental biology · 2026Review
- Erectile dysfunction among diabetic patients in Western Uganda: prevalence and associated factors in a multicentre study across three selected clinics.BMC endocrine disorders · 2025Article
- Prescription Trends and the Role of Cardiologists in the Diagnosis and Treatment of Erectile Dysfunction.Journal of cardiovascular development and disease · 2025Article
- Systemic impacts of diabetes on spermatogenesis and intervention strategies: multilayered mechanism analysis and cutting-edge therapeutic approaches.Reproductive biology and endocrinology : RB&E · 2025Review
- The Impact of Glucagon-like Peptide-1 Receptor Agonists on Erectile Function: Friend or Foe?Biomolecules · 2025Review
- Erectile Dysfunction in Diabetes Mellitus: A Comprehensive Narrative Review of Pathophysiology, Genetic Association Studies and Therapeutic Approaches.Endocrinology, diabetes & metabolism · 2025Review
- Prevalence and determinants of erectile dysfunction among male type 2 diabetes mellitus patients with chronic kidney disease: a cross-sectional study.Translational andrology and urology · 2025Article
- A systematic review and meta-analysis of follicle-stimulating hormone levels among men with type 2 diabetes.Basic and clinical andrology · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Previous studies have established that diabetes mellitus (DM) markedly raises the risk of developing erectile dysfunction (ED). Despite extensive investigations, the risk factors associated with ED in diabetic men have yet to be unequivocally determined, owing to incongruent and inconclusive results reported in various studies. Objective: The objective of this systematic review and meta-analysis was to assess the risk factors for ED in men with DM. Methods: A comprehensive systematic review was conducted, encompassing studies published in the PubMed, Scopus and Embase databases up to August 24th, 2023. All studies examining the risk factors of ED in patients with DM were included in the analysis. To identify significant variations among the risk factors, odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) were employed. The risk of bias was evaluated using the Newcastle-Ottawa Scale(NOS) for longitudinal studies and the Agency for Healthcare Research and Quality Scale(AHRQ) for cross-sectional studies. Results: A total of 58 studies, including a substantial participant pool of 66,925 individuals diagnosed with DM, both with or without ED, were included in the meta-analysis. Mean age (OR: 1.31, 95% CI=1.24-1.37), smoking status (OR: 1.32, 95% CI=1.18-1.47), HbA1C (OR: 1.44, 95% CI=1.28-1.62), duration of DM (OR: 1.39, 95% CI=1.29-1.50), diabetic neuropathy (OR: 3.47, 95% CI=2.16-5.56), diabetic retinopathy (OR: 3.01, 95% CI=2.02-4.48), diabetic foot (OR: 3.96, 95% CI=2.87-5.47), cardiovascular disease (OR: 1.92, 95% CI=1.71-2.16), hypertension (OR: 1.74, 95% CI=1.52-2.00), microvascular disease (OR: 2.14, 95% CI=1.61-2.85), vascular disease (OR: 2.75, 95% CI=2.35-3.21), nephropathy (OR: 2.67, 95% CI=2.06-3.46), depression (OR: 1.82, 95% CI=1.04-3.20), metabolic syndrome (OR: 2.22, 95% CI=1.98-2.49), and diuretic treatment (OR: 2.42, 95% CI=1.38-4.22) were associated with increased risk factors of ED in men with DM. Conclusion: Our study indicates that in men with DM, several risk factors for ED have been identified, including mean age, HbA1C, duration of DM, diabetic neuropathy, diabetic retinopathy, diabetic foot, cardiovascular disease, hypertension, microvascular disease, vascular disease, nephropathy, depression, metabolic syndrome, and diuretic treatment. By clarifying the connection between these risk factors and ED, clinicians and scientific experts can intervene and address these risk factors, ultimately reducing the occurrence of ED and improving patient management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.